Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter sub-study of the EMPA-Heart CardioLink-6 Randomised Trial
2 September 2019 (08:30 - 12:30)
Organised by:
Abstract
About the speaker
St. Michael's Hospital, Toronto (Canada)
8 More presentations in this session
Access the full session
The Event
ESC Congress 2019
2 September 2019
08:30 CET
